AbbVie agrees to acquire Apogee Therapeutics in a cash deal valued at about $10.9 billion, according to multiple reports. The acquisition is described as AbbVie’s largest deal in more than half a decade, and is positioned to strengthen the company’s immunology and inflammation portfolio. Several outlets note that the transaction adds drug development assets related to inflammatory diseases, including atopic dermatitis (commonly known as eczema). Bloomberg also highlights that the deal would enhance AbbVie’s dermatology presence through the addition of atopic dermatitis treatments. Other coverage frames the purchase as part of a broader wave of mergers and acquisitions in the biopharmaceutical sector. STAT reports the price as nearly $11 billion and identifies Apogee as the developer of an experimental atopic dermatitis drug. Overall, the sources agree on the key terms of the transaction—cash consideration and an approximately $10.9 billion value—and on the strategic rationale centered on expanding AbbVie’s footprint in immunology, inflammation, and dermatology-focused therapies.